The U.S. Health Regulatory Agency approved it this Thursday The second pill against Kovit-19, Created Merck, Omigron is another easy-to-use drug to combat the growing tide of infections.
Accreditation by the Food and Drug Administration (FDA) Occurs one day after delivery by the company Approval of competing drug Pfizer. This pill has the potential to become the first line treatment for the virus, thanks to its excellent benefits and mild side effects.
as a consequence, Merck’s pill is expected to play a lesser role against the infection than expected a few weeks ago. Its ability to cope with severe COVID-19 is far less than initially reported, and the label of the drug warns of serious safety concerns such as the potential for birth defects.
The Food and Drug Administration (FDA) has approved Merck’s medication for adults with early symptoms of COVID-19, including the elderly and those with conditions such as obesity and disease who are at higher risk in hospital. The UK first approved the pill in early November.
Known as Molnupravir, Merck will have a warning against using the drug during pregnancy. According to the FDA, women who are capable of giving birth should use birth control a few days after treatment.
After the FDA advisory board approved the drug in short supply last month, it warned that its use should be strictly applicable to the most beneficial patients.
The Pfizer tablet works differently and does not have the same risks. In addition, Pfizer tripled drug trials, reducing hospital admissions and mortality by almost 90% among high-risk patients, compared with 30% of Merck.
Some experts wonder if Merck will play a major role in the United States.
“As long as the Pfizer tablet is large enough I think it will not be usedReferring to Merck medicine, Dr. Gregory Poland of the Mayo Clinic said, “There can be no reason because it is less effective and has a higher risk of side effects.”
The federal government has agreed to buy enough medicine to treat 3.1 million people.
The United States pays about $ 700 for each course of Merck medicine, and patients are required to take four tablets twice a day for five days. A study A study by Harvard University and King’s College London estimated that each treatment for 40 tablets would cost about $ 18.
Merck drug introduces small errors in the genetic code of the corona virus to stop its reproduction. That genetic effect has raised concerns that the drug could cause mutations in the human embryo and trigger more malignant strains of the virus. But according to FDA scientists, the risk of variations is largely theoretical because people take drugs for a very short period of time.
For now, the FDA’s decision provides another viable option against the virus that has killed more than 800,000 Americans, with health officials preparing for a record number of cases, hospitalizations and deaths from the Omigron variant. Antiviral pills, including Merck, are expected to work against Omigran because they do not target the spike protein, where there are anxious mutations of the variant.
The FDA based its results on the fact that approximately 7% of patients taking the drug ended up in the hospital and one died within 30 days. This compares with 10% of hospital-admitted patients taking placebo and nine deaths.
(With AP info)